{"id":827,"date":"2019-05-16T07:39:36","date_gmt":"2019-05-16T07:39:36","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=827"},"modified":"2022-04-04T17:16:40","modified_gmt":"2022-04-04T15:16:40","slug":"spin-offs","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/innovation\/spin-offs\/","title":{"rendered":"Spin-offs"},"content":{"rendered":"\n

\n\t\tSpin-offs\n\t<\/h2>\n

\n\t\tWhat is a spin-off?\n\t<\/h3>\n\t

A spin-off is a small, newly created company, created for the development and\/or use of products or services based on technologies or knowledge originating from research activities carried out at a public or private research centre or institution.<\/p>\n

\n\n<\/section>\n\t\t 5\n\t\t\t\t\t2019\n\t\t 6\n\t\t\t\t\t2020\n\t\t 6\n\t\t\t\t\t2021\n\t\t 7\n\t\t\t\t\t2022\n\t\t\t\t\"spin-offs_0\"\n

\n\t\tCONTACT\n\t<\/h4>\n\t

Bussines Development and Innovation Area<\/a><\/p>\n\t\t\t\t\"admit_0\"\n

\n\t\tADmit Therapeutics (ADmit)\n\t<\/h6>\n\t

This is a spin-off created with the objective of developing and marketing a new type of Kit for the early detection of Alzheimer’s by means of an epigenetic blood analysis, with measurement of methylcytosine in mitochondrial DNA.<\/p>\n

The main aim of ADmit Therapeutics is to develop a cheap, fast and painless diagnostic kit that can be used to detect Alzheimer’s during the early stages of the disease in patients with mild cognitive impairment, both in primary care as well as in hospitals and private physician offices. With the focus of a prevention plan in older individuals, early detection would allow rapid intervention to reduce disease progression, improve the patient’s quality of life and minimise the associated direct and indirect costs for both health systems and families.<\/p>\n

\n\t\t\n\t\thttp:\/\/www.admit-therapeutics.com\/\n\t\t<\/a>\n\t<\/h3>\n\t\t\t\t\"xenopat_0\"\n
\n\t\tXenopat\n\t<\/h6>\n\t

This is a spin-off that offers services focussed on assistance in the development of cancer drugs and personalised oncology treatment.<\/p>\n

Xenopat offers its services through the use of Orthoxenografts\u00ae, mouse models in which a small piece of human tumour (xenograft) is implanted in the same organ of origin (orthotopic patient-derived xenografts (PDXs)).<\/p>\n

In addition, it has exclusive rights not only to generate new Orthoxenografts\u00ae based on customer needs but also to exploit the OrthoXenoBank\u00ae, a collection composed of more than 200 models that represent the most frequent histological subtypes of the following locations: colon, lung, ovary, pancreas, endometrium, sarcoma, head and neck, liver, and germ cells, among others.<\/p>\n

\n\t\t\n\t\t
Home<\/a><\/blockquote>